|Bid||76.50 x 1100|
|Ask||77.90 x 800|
|Day's range||75.58 - 77.27|
|52-week range||59.78 - 80.49|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||15.12|
|Earnings date||31 Jan 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||78.33|
MARLBOROUGH, Mass., December 01, 2022--Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
MARLBOROUGH, Mass., November 25, 2022--Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.